551 related articles for article (PubMed ID: 15572275)
1. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
3. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
5. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Tollefson GD; Birkett M; Koran L; Genduso L
J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
7. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Sevincok L; Topuz A
J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
[TBL] [Abstract][Full Text] [Related]
8. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
9. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E
Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510
[TBL] [Abstract][Full Text] [Related]
10. Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
Jacobsen FM
J Clin Psychiatry; 1995 Sep; 56(9):423-9. PubMed ID: 7545159
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
12. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
13. Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study.
Veznedaroglu B; Ercan ES; Kayahan B; Varan A; Bayraktar E
Hum Psychopharmacol; 2003 Dec; 18(8):635-40. PubMed ID: 14696023
[TBL] [Abstract][Full Text] [Related]
14. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study.
Zohar J; Kaplan Z; Benjamin J
J Clin Psychiatry; 1994 Mar; 55(3):86-8. PubMed ID: 8071253
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
Mundo E; Guglielmo E; Bellodi L
Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
17. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
Haas M; Delbello MP; Pandina G; Kushner S; Van Hove I; Augustyns I; Quiroz J; Kusumakar V
Bipolar Disord; 2009 Nov; 11(7):687-700. PubMed ID: 19839994
[TBL] [Abstract][Full Text] [Related]
18. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
[TBL] [Abstract][Full Text] [Related]
19. [Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder].
Salmerón JM; Alcántara AG; Barcia D
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(6):399-402. PubMed ID: 9972593
[TBL] [Abstract][Full Text] [Related]
20. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
Reznik I; Sirota P
Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
